Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more
Bio-Gene Technology Ltd - Asset Resilience Ratio
Bio-Gene Technology Ltd (BGT) has an Asset Resilience Ratio of 20.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Bio-Gene Technology Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bio-Gene Technology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$300.00K | 20.35% |
| Total Liquid Assets | AU$300.00K | 20.35% |
Asset Resilience Insights
- Good Liquidity Position: Bio-Gene Technology Ltd maintains a healthy 20.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Bio-Gene Technology Ltd Industry Peers by Asset Resilience Ratio
Compare Bio-Gene Technology Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Bio-Gene Technology Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Bio-Gene Technology Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 23.26% | AU$500.00K | AU$2.15 Million | -24.22pp |
| 2024-06-30 | 47.47% | AU$1.50 Million | AU$3.16 Million | +46.46pp |
| 2022-06-30 | 1.02% | AU$74.20K | AU$7.30 Million | -77.64pp |
| 2021-06-30 | 78.65% | AU$3.93 Million | AU$5.00 Million | -4.82pp |
| 2018-06-30 | 83.48% | AU$6.40 Million | AU$7.67 Million | +62.30pp |
| 2017-06-30 | 21.17% | AU$2.00 Million | AU$9.45 Million | -- |